Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

The Holmium Platform is now commercially available following the launch of Q-Suite™ treatment planning

22/09/2020 - LEUVEN, BELGIUM

Following the acquisition of Quirem Medical in July 2020, Terumo Europe is pleased to announce that the latest version of its Holmium-166 specific dosimetry software Q-SuiteTM has been fully launched today following gaining CE Mark. This latest version includes a treatment planning functionality. This additional functionality makes up The Holmium Platform, three fully integrated products (QuiremScout® microspheres, QuiremSpheres® microspheres and Q-SuiteTM software) delivering individualized SIRT at its full potential.


"The introduction of treatment planning within the Q-SuiteTM software is an essential piece of the puzzle that makes up The Holmium Platform" Laurent Domas, VP Global Interventional Oncology Strategy and Therapy Development at Terumo. "We now have the first fully integrated SIRT platform that combines the QuiremScout® work-up product the QuiremSpheres® treatment product and the Q-Suite™ software. This software enables improved patient selection and individualized treatment planning. We will now design a clinical program to further develop evidence to demonstrate the benefit of Holmium SIRT."

 

"With this additional treatment planning functionality, alongside the benefits Holmium-166 SIRT can bring to patients, we have been able to further optimize how we plan our treatments." Prof. Dr. M. Lam, Head of Nuclear medicine at the University Medical Center Utrecht (UMCU) said, "Now that we have the full Holmium Platform we believe that we can continue to optimize SIRT and through the clinical programs that are being setup, we believe we can really help to reinforce where SIRT can make a difference for liver cancer patients."

 

About Terumo Europe

Terumo Europe, founded in 1971, is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in four main business units: Hospital and Laboratory Systems, Global Pharmaceutical Solutions, Interventional Systems and CardioVascular Products. Terumo Europe EMEA headquarters and production facilities are located in Haasrode (Belgium), production facility in Knowsley (UK) and sales units across EMEA.

Please visit www.terumo-europe.com for more information.

 

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide, to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been bolstering healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.